Highlights for July 2016:
- Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis
- Zydus Cadila has signed a non-exclusive, royalty-free agreement with The Medicines Patent Pool (MPP) for the generic production of daclatasvir for Hepatitis C
- Dr. Reddy’s completes acquisition of eight ANDAs in the US from Teva Pharmaceutical Industries
- Cipla will invest USD 89 million to build a new production facility in South Africa that will focus on the manufacturing of biosimilars.
- Granules to acquire 12.5% stake in US pharma
- Shanghai Fosun to buy Gland Pharma for USD 1.4 bn.
- Aurobindo Pharma mulls bidding for Teva Pharmaceutical's USD 1.5 billion drug portfolio
For more such news and updates, please join our Group "Global Life Science Business in India" on LinkedIn.
Aagami Updates:
- Dr. Linda Pullan joined Aagami Inc. as a partner Consultant.
- Based in Southern California, Linda is a Ph.D., with over 25 years of rich pharmaceutical and biotech experience in research and licensing, business development, R&D and consulting.
- She has worked each year on 5+ signed deals and has a great deal sheet with more than 50 large, mid and small size deals (licensing as large as $100MM upfront, several options, and university licenses - for Preclinical to Phase III).
- She has authored 66 scientific literature publications and has also been honored as a Lecturer, Advisor, Reviewer, and Speaker.